MedImmune was founded in 1988 and has built on the local legacy of Cambridge Antibody Technology. The company’s pioneering research has led to ground-breaking achievements, including the development and commercialisation of Synagis® (palivizumab) and Fluenz® (nasal spray, suspension influenza vaccine [live attenuated]). In addition, MedImmune discoveries have also helped lead to a human papillomavirus vaccine, the important anti-tumour necrosis factor (TNF) antibody and the first active systemic lupus erythematosus treatment in decades.
“As part of our 25th anniversary celebrations, MedImmune will make a £3,200 donation to the Macmillan Cancer Support, which was an organisation selected by Cambridge employees. MedImmune is committed to discovering novel treatments in oncology, one of the company’s core therapeutic areas,” said Jane Osbourn, Site Leader and Vice President of R&D at MedImmune in Cambridge.
“As one of the largest biotechnology companies in Cambridge, MedImmune’s Cambridge site employs more than 500 people and is a significant contributor to the local economy and local life science sector. We are committed to the Cambridge community, and look forward to continuing to play a leading role which will be strengthened by the arrival of colleagues from AstraZeneca.”
Carla Pilsworth, Cambridge Fundraising Manager for Macmillan Cancer Support, commented: “We are immensely grateful to the team at MedImmune for selecting our charity. With treatments improving and the population ageing, more people are living with the illness than ever before. Our ambition is to reach and improve the lives of everyone affected by cancer, no matter who they are or where they live and inspire millions to do the same. In Cambridgeshire we fund over 90 medical professionals including nurses, GPs, dieticians and speech and language therapists. The money that has been so generously given by MedImmune will help us to maintain our vital support services.”
About MedImmune
MedImmune is the worldwide biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience, and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Maryland, USA, one of AstraZeneca’s three global R&D centres. For more information, please visit www.medimmune.com
*******
Media Contact:
Tracy Rossin, MedImmune
[email protected]
001 301 398 1468
_______________________________________________________